Ipamorelin
ipamorelin
research_page
Ipamorelin Peptide Research
Ipamorelin Peptide Research
Assessing ipamorelin as a selective growth-hormone secretagogue
Ipamorelin is one of the best-known selective GH secretagogues in the peptide space.
Ipamorelin is one of the best-known selective GH secretagogues in the peptide space.
Some of the biggest claims about Ipamorelin move faster than the evidence. This page focuses on what the published research actually shows.
Ipamorelin is one of the best-known selective GH secretagogues in the peptide space. It is generally positioned as a ghrelin-receptor agonist with a cleaner and more selective growth-hormone release profile than older GHRPs.
It acts at the ghrelin receptor to stimulate pulsatile GH release. The practical appeal is the idea of endogenous GH support without direct GH replacement, often with fewer off-target endocrine effects than older secretagogues in theory.
Clinical interest centers on hormone optimization, recovery, body composition, and GH-axis support. It is often used as the comparator benchmark for other secretagogues such as hexarelin and sermorelin-based protocols.
The literature includes human pituitary testing, GH-secretagogue biology reviews, and broader endocrine comparisons. The evidence supports real GH stimulation, but not the kind of long-term body-composition outcomes seen with approved obesity or GH-deficiency drugs.
Concerns include fluid retention, headache, altered glucose handling, and inappropriate use in people with contraindications to GH-axis stimulation. Product quality and overstatement of results are common practical risks.
Ipamorelin is one of the more mechanistically coherent and selective secretagogues, but it remains an endocrine tool rather than an evidence-equivalent replacement for approved therapies.
Moderate
Clinical
Compounded/Off-label Context
gh-secretagogue
ghrp|hormone-optimization|performance
informational
hormone-optimization
muscle-growth
performance
cjc-1295-ipamorelin|hexarelin|sermorelin|tesamorelin|somatropin
apex-stack|performance-stack|gh-optimization-stack
hormone-optimization|muscle-growth|performance
ipamorelin-vs-sermorelin|cjc-1295-vs-ipamorelin|hexarelin-vs-ipamorelin
study059|study060|study091|study109|study021|study108
Ipamorelin peptide research
ipamorelin studies|ipamorelin GH release|ipamorelin vs sermorelin
Ipamorelin Research: Mechanism, Studies, and Evidence
Scientific overview of ipamorelin, including ghrelin-receptor signaling, human GH data, and how it compares with sermorelin and hexarelin.
Ipamorelin Research: Mechanism, Studies, and Evidence
Scientific overview of ipamorelin, including ghrelin-receptor signaling, human GH data, and how it compares with sermorelin and hexarelin.
What is ipamorelin?
Ipamorelin is a ghrelin-receptor agonist peptide designed to stimulate endogenous growth-hormone release in a relatively selective manner.
Is ipamorelin the same as sermorelin?
No. Ipamorelin works through the ghrelin receptor, while sermorelin is a GHRH analog that stimulates the pituitary through a different upstream pathway.
What is ipamorelin?
Ipamorelin is a ghrelin-receptor agonist peptide designed to stimulate endogenous growth-hormone release in a relatively selective manner.
Ipamorelin is one of the more mechanistically coherent and selective secretagogues, but it remains an endocrine tool rather than an evidence-equivalent replacement for approved therapies.
Ipamorelin is one of the more mechanistically coherent and selective secretagogues, but it remains an endocrine tool rather than an evidence-equivalent replacement for approved therapies
Peptiders Research Team
Peptiders Clinical Review Board
MedicalWebPage
Peptide
Endocrine
/images/ipamorelin.jpg
Ipamorelin peptide research overview
published